Clinical Efficacy of Therapy with Recombinant Human Interferon α1b in Hand, Foot, and Mouth Disease with Enterovirus 71 Infection

Xueyong Huang; Xi Zhang; Fang Wang; Haiyan Wei; Hong Ma; Meili Sui; Jie Lu; Huaili Wang; J Stephen Dumler; Guangyao Sheng; Bianli Xu

doi:10.1371/journal.pone.0148907

Clinical Efficacy of Therapy with Recombinant Human Interferon α1b in Hand, Foot, and Mouth Disease with Enterovirus 71 Infection

PLoS One. 2016 Feb 16;11(2):e0148907. doi: 10.1371/journal.pone.0148907. eCollection 2016.

Authors

Xueyong Huang¹, Xi Zhang², Fang Wang³, Haiyan Wei¹, Hong Ma¹, Meili Sui⁴, Jie Lu⁴, Huaili Wang⁵, J Stephen Dumler⁶, Guangyao Sheng⁵, Bianli Xu¹

Affiliations

¹ Henan Center for Disease Control and Prevention, Zhengzhou, China.
² Children's Hospital of Kaifeng City, Zhengzhou, China.
³ Children's Hospital of Zhengzhou City, Zhengzhou, China.
⁴ College of Public Health, Zhengzhou University, Zhengzhou, China.
⁵ The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
⁶ Departments of Pathology and Microbiology & Immunology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.

Abstract

A rapid expansion of HFMD with enterovirus 71 infection outbreaks has occurred and caused deaths in recent years in China, but no vaccine or antiviral drug is currently available for EV71 infection. This study aims to provide treatment programs for HFMD patients. We conducted a randomized, double-blind, controlled trial and evaluated clinical efficacy of therapy with rHuIFN-α1b in HFMD patients with EV71 infection. There were statistical differences in outcomes including the fever clearance time, healing time of typical skin or oral mucosa lesions, and EV71 viral load of the HFMD patients among ultrasonic aerosol inhalation group, intramuscular injection group and control group. rHuIFN-α1b therapy reduced the fever clearance time, healing time of typical skin or oral mucosa lesions, and EV71 viral load in children with HFMD.

Trial registration: Chinese Clinical Trial Registry ChiCTR-TRC-14005153.

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Child, Preschool
China
Double-Blind Method
Enterovirus A, Human / drug effects
Enterovirus A, Human / pathogenicity
Enterovirus Infections / drug therapy*
Enterovirus Infections / genetics
Enterovirus Infections / pathology
Enterovirus Infections / virology
Female
Hand, Foot and Mouth Disease / drug therapy*
Hand, Foot and Mouth Disease / genetics
Hand, Foot and Mouth Disease / pathology
Hand, Foot and Mouth Disease / virology
Humans
Infant
Interferon-alpha / administration & dosage*
Interferon-alpha / genetics
Male
Recombinant Proteins / administration & dosage*
Recombinant Proteins / genetics
Treatment Outcome

Substances

Interferon-alpha
Recombinant Proteins

Associated data

ChiCTR/CHICTR-TRC-14005153

Grants and funding

This study was supported by grants from Henan Province Health Department and National Health and Family Planning Commission of the People’s Republic of China Co-build Project (201001015), and Science and Technology Bureau of Henan Province (122102310268).